Dosing & Uses
Dosage Forms & Strengths
injectable solution
- 37-2,960 MBq/mL (1-80 mCi/mL) per vial at calibration date and time
Prostate Cancer PET Imaging
Indicated for positron-emission tomography (PET) of prostate-specific membrane antigen (PSMA)–positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level
333 MBq (9 mCi), range of 296-370 MBq (8-10 mCi), administered as a single bolus IV injection
Safety and efficacy not established
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Contraindicated (0)
Serious - Use Alternative (0)
Monitor Closely (0)
Minor (0)
Adverse Effects
1-10%
Headache (2%)
Dysgeusia (2%)
Fatigue (1%)
<1%
Hypersensitivity (0.2%)
Warnings
Contraindications
None
Cautions
Monitor for hypersensitivity reactions, particularly in patients with a history of allergy to other drugs and foods; reactions may not be immediate; trained staff and resuscitation equipment should always be available
Risk of image misinterpretation
- Imaging interpretation errors can occur
- A negative image does not rule out presence of prostate cancer and a positive one does not confirm presence of prostate cancer
- Drug uptake is not specific for prostate cancer and may occur with other types of cancer, nonmalignant processes, and in normal tissues
- Clinical correlation, which may include histopathological evaluation of suspected prostate cancer site, is recommended
Radiation risks
- Diagnostic radiopharmaceuticals expose patients to radiation
- Radiation exposure is associated with a dose-dependent increased risk of cancer
- Ensure safe drug handling and patient preparation procedures to protect patients and healthcare providers from unintentional radiation exposure
Drug interaction overview
-
Androgen-deprivation therapy (ADT) and other therapies targeting the androgen pathway
- ADT and other therapies targeting the androgen pathway (eg, androgen receptor antagonists) may result in changes in uptake of piflufolastat F18 in prostate cancer
- Effect of these therapies on performance has not been established
Pregnancy & Lactation
Pregnancy
Not indicated for use in females
There is no information on the risk of adverse developmental outcomes in pregnant females or animals
All radiopharmaceuticals, including piflufolastat F18, may potentially cause fetal harm depending on fetal stage of development and magnitude of radiation dose
Lactation
Not indicated for use in females
There is no information on drug presence in human milk, effects on breastfed infants, or effects on milk production
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Radiolabeled PSMA inhibitor imaging agent
Binds to cells that express PSMA, including malignant prostate cancer cells
Fluorine-18 (F18) is a beta-positive–emitting radionuclide that enables PET
Distribution
Distributes to kidneys (16.5% of administered activity), liver (9.3%), and lung (2.9%), within 60 minutes of IV administration
Distribution half-life: 0.17 hr
Elimination
Half-life: 3.47 hr
Excretion: Urine (~50% [first 8 hr post dose])
Administration
IV Preparation
Use aseptic technique and radiation shielding when withdrawing and administering
Visually inspect solution; do not use if it contains particulate matter or is cloudy or discolored; solution is clear and colorless
Calculate the necessary volume to administer based on calibration time and required dose; piflufolastat F18 may be diluted with 0.9% NaCl
Assay dose in a suitable dose calibrator before administration
Radiation safety
- Piflufolastat F18 is a radioactive drug; only authorized persons qualified by training and experience should receive, use, or administer
- Handle with appropriate safety measures to minimize radiation exposure during administration
- Use waterproof gloves and effective radiation shielding, including syringe shields, when preparing and handling
Patient preparation
- Instruct patients to drink water to ensure adequate hydration before administration and continue drinking and voiding frequently during the first few hours following administration to reduce radiation exposure
IV Administration
Administer IV over 1-2 minutes
Follow injection with IV flush of 0.9% NaCl
Dispose of any unused drug in compliance with radiopharmaceutical regulations
Image acquisition
Start 60 minutes after administration
Starting image acquisition >90 minutes after injection may affect imagining performance
Advise patients to void immediately before image acquisition
Position patient supine with arms above head
Start image acquisition from mid thigh and proceed to skull vertex
Scan duration: 12-40 minutes depending on number of bed positions (typically 6-8) and acquisition time per bed position (typically 2-5 minutes)
Storage
Unopened vials
- Store at 20-25ºC (68-77ºF)
- Store upright in original container with radiation shielding
- Expiration date and time are provided on container label
- Use within 10 hr from the time of the end of synthesis
Images
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.